Researchers in the UK have said that an algorithm developed using artificial intelligence could help doctors decide more quickly if a patient has suffered a heart attack,
BenevolentAI has reported disappointing results in a phase 2 trial of lead drug BEN-2293 in atopic dermatitis (AD), as the drug was unable to show the hoped-for effect on